---
layout: default
title: Panitumumab
parent: 僅模型預測 (L5)
nav_order: 474
evidence_level: L5
indication_count: 2
---

# Panitumumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **2** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Panitumumab: From Metastatic Colorectal Cancer to Drug-Induced Osteoporosis

## One-Sentence Summary

> Panitumumab is a fully human anti-EGFR monoclonal antibody, established for treating RAS wild-type metastatic colorectal cancer.
> The TxGNN model predicts it may be effective for **drug-induced osteoporosis**,
> but this prediction is currently supported by **0 clinical trials** and **0 publications** — it is a model-only hypothesis with no known mechanistic pathway.

*Note: the evidence pack's `original_indications` field was empty and `original_moa` is a data gap. The original indication above reflects panitumumab's publicly known labeled use, not a field extracted from this evidence pack.*

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Metastatic colorectal cancer (EGFR-expressing, RAS wild-type) — general drug knowledge; not present in the supplied dataset |
| Predicted New Indication | Drug-induced osteoporosis |
| TxGNN Prediction Score | 99.13% |
| Evidence Level | L5 |
| Saudi Arabia Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for panitumumab in this evidence pack. Based on known information, panitumumab is a fully human IgG2 monoclonal antibody that inhibits EGFR (epidermal growth factor receptor) signaling on tumor cells, and its efficacy in metastatic colorectal cancer is well established.

However, the mechanistic link to drug-induced osteoporosis is weak. Panitumumab's known adverse effects — acneiform rash, hypomagnesemia, and infusion reactions — do not point to a known pathway affecting osteoblast/osteoclast balance or bone remodeling. The high TxGNN score (0.991) appears to reflect proximity within the knowledge graph's embedding space rather than any documented biological or clinical relationship between EGFR inhibition and bone loss.

Given the absence of supporting clinical trials, literature, or a plausible mechanism, this prediction should be treated as a graph-similarity-driven hypothesis requiring independent mechanistic validation before further pursuit.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## Saudi Arabia Market Information

Panitumumab currently holds no market authorization in Saudi Arabia (0 licenses; market status: not marketed), so no product/authorization data is available.

---

## Cytotoxicity

Panitumumab is an antineoplastic biologic (anti-EGFR monoclonal antibody used in oncology).

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (anti-EGFR monoclonal antibody) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Additional Predicted Indication (Rank 2)

A second candidate, **severe nonproliferative diabetic retinopathy** (TxGNN score 99.05%, rank 13043), was also predicted, but likewise has 0 supporting trials/literature (evidence level L5, recommendation: Hold). The associated rationale notes that anti-EGFR agents have only sporadic reports of ocular surface toxicity (conjunctivitis, eyelash changes), not the VEGF-driven vascular pathology underlying diabetic retinopathy — so this candidate is even less mechanistically plausible than the primary one.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This candidate rests solely on a TxGNN embedding score (L5) with zero clinical trials, zero literature, and no plausible mechanistic pathway connecting EGFR inhibition to bone metabolism. A **Blocking** data gap also exists — no TFDA/SFDA package insert safety data is available, precluding even a preliminary S1 safety assessment.

**To proceed, the following is needed:**
- SFDA/TFDA package insert data (warnings, contraindications, DDI) — currently blocking
- Confirmed mechanism of action (MOA) from DrugBank or primary literature
- Preclinical or mechanistic studies linking EGFR pathway inhibition to bone metabolism
- At minimum, an observational study or case series supporting biological plausibility before advancing past S0
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

